Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURANASDAQ:CGCNASDAQ:EPIXNASDAQ:IMMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.89-0.8%$5.76$4.35▼$12.38$296.08M0.43210,758 shs158,183 shsCGCCanopy Growth$1.83-5.2%$1.23$0.77▼$10.04$336.47M0.795.82 million shs8.14 million shsEPIXESSA Pharma$1.69+1.8%$1.65$1.40▼$7.88$75.02M1.69339,621 shs9,320 shsIMMPImmutep$1.94-1.5%$1.74$1.32▼$3.05$283.32M1.8219,331 shs86,502 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-0.84%-1.01%+2.26%-21.57%-17.74%CGCCanopy Growth-5.18%+10.24%+47.58%+12.27%-80.55%EPIXESSA Pharma+1.81%-1.17%-3.98%-1.74%-72.74%IMMPImmutep-1.52%-4.43%+19.75%+1.04%-37.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.833 of 5 stars3.62.00.00.04.03.30.0CGCCanopy Growth0.8712 of 5 stars0.52.00.00.02.30.01.3EPIXESSA Pharma1.9767 of 5 stars2.03.00.00.03.12.51.3IMMPImmutep1.3211 of 5 stars3.52.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.75286.25% UpsideCGCCanopy Growth 1.00Sell$2.009.29% UpsideEPIXESSA Pharma 2.00Hold$2.0018.34% UpsideIMMPImmutep 3.00Buy$7.00260.82% UpsideCurrent Analyst Ratings BreakdownLatest EPIX, CGC, IMMP, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/ACGCCanopy Growth$276.75M1.22N/AN/A$2.72 per share0.67EPIXESSA PharmaN/AN/AN/AN/A$2.68 per shareN/AIMMPImmutep$5.14M55.12N/AN/A$1.05 per share1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%N/ACGCCanopy Growth-$487.23M-$3.80N/AN/AN/A-156.98%-56.52%-24.18%5/30/2025 (Confirmed)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-24.61%-23.87%8/4/2025 (Estimated)IMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)Latest EPIX, CGC, IMMP, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28N/AN/AN/A$71.84 millionN/A5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AIMMPImmutepN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47CGCCanopy Growth0.743.522.58EPIXESSA PharmaN/A33.1233.12IMMPImmutep0.0118.2518.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%CGCCanopy Growth3.33%EPIXESSA Pharma75.12%IMMPImmutep2.32%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%CGCCanopy Growth1.30%EPIXESSA Pharma15.50%IMMPImmutep3.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableCGCCanopy Growth3,150183.87 million153.39 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableEPIX, CGC, IMMP, and AURA HeadlinesRecent News About These CompaniesImmutep (NASDAQ:IMMP) Upgraded by Wall Street Zen to "Hold" RatingMay 24 at 11:22 AM | marketbeat.comImmutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 16, 2025 | manilatimes.netImmutep reports promising lung cancer trial resultsMay 16, 2025 | investing.comImmutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15, 2025 | finance.yahoo.comIs Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comImmutep’s Efti Combination Shows Promising Results in Lung Cancer TrialMay 14, 2025 | tipranks.comImmutep Limited: Surging On Positive Head And Neck DataMay 8, 2025 | seekingalpha.comImmutep (NASDAQ:IMMP) Stock Crosses Below 50 Day Moving Average - Time to Sell?May 5, 2025 | marketbeat.comImmutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPSMay 5, 2025 | manilatimes.netImmutep’s Efti Shows Promising Results in Head and Neck Cancer TrialMay 4, 2025 | tipranks.comImmutep Quarterly Activities Report Q3 FY25April 29, 2025 | finance.yahoo.comImmutep Limited Reports First Patient Dosed in TACTI-004 Phase III Lung Cancer Trial and Updates on Clinical ProgressApril 29, 2025 | quiverquant.comImmutep Advances Cancer Trials with Promising DevelopmentsApril 28, 2025 | tipranks.comImmutep (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average - Here's WhyApril 27, 2025 | marketbeat.comImmutep to Participate in Upcoming Investor ConferencesApril 2, 2025 | globenewswire.comImmutep to Engage in Key Investor ConferencesApril 1, 2025 | tipranks.comImmutep: A Small Company With A Pipeline Resembling Big PharmaMarch 31, 2025 | seekingalpha.comFirst Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerMarch 25, 2025 | finance.yahoo.comImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025March 20, 2025 | markets.businessinsider.comImmutep Limited to Present TACTI-004 Phase III Trial Data at European Lung Cancer Congress 2025March 20, 2025 | quiverquant.comImmutep to Present Pivotal Lung Cancer Trial at ELCC 2025March 19, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPIX, CGC, IMMP, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$5.89 -0.05 (-0.84%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.94 +0.05 (+0.85%) As of 05/23/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Canopy Growth NASDAQ:CGC$1.83 -0.10 (-5.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.ESSA Pharma NASDAQ:EPIX$1.69 +0.03 (+1.81%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.30%) As of 05/23/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Immutep NASDAQ:IMMP$1.94 -0.03 (-1.52%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.94 0.00 (0.00%) As of 05/23/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
